Considerations When Treating Patients with Good-risk Germ Cell Tumors

Aditya Bagrodia; Costantine Albany; Clint Cary

doi:10.1016/j.euf.2019.01.002

Considerations When Treating Patients with Good-risk Germ Cell Tumors

Aditya Bagrodia, Costantine Albany, Clint Cary

Research output: Contribution to journal › Editorial › peer-review

Abstract

Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

Original language	English (US)
Pages (from-to)	1195-1198
Number of pages	4
Journal	European Urology Focus
Volume	6
Issue number	6
DOIs	https://doi.org/10.1016/j.euf.2019.01.002
State	Published - Nov 15 2020

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.euf.2019.01.002

Cite this

@article{abbb22f344a74b01a047add1dbd8ef91,

title = "Considerations When Treating Patients with Good-risk Germ Cell Tumors",

abstract = "Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.",

author = "Aditya Bagrodia and Costantine Albany and Clint Cary",

note = "Publisher Copyright: {\textcopyright} 2019 European Association of Urology",

year = "2020",

month = nov,

day = "15",

doi = "10.1016/j.euf.2019.01.002",

language = "English (US)",

volume = "6",

pages = "1195--1198",

journal = "European Urology Focus",

issn = "2405-4569",

publisher = "Elsevier BV",

number = "6",

}

TY - JOUR

T1 - Considerations When Treating Patients with Good-risk Germ Cell Tumors

AU - Bagrodia, Aditya

AU - Albany, Costantine

AU - Cary, Clint

PY - 2020/11/15

Y1 - 2020/11/15

N2 - Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

AB - Three cycles of bleomycin, etoposide, and cisplatin or four cycles of etoposide and cisplatin are options for patients with good-risk germ cell tumors. Despite no significant differences in clinical outcomes in a randomized trial, studies suggest variable impact on postchemotherapy retroperitoneal lymph node dissection histology, which may help inform treatment decisions.

UR - http://www.scopus.com/inward/record.url?scp=85059700928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059700928&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.01.002

DO - 10.1016/j.euf.2019.01.002

M3 - Editorial

C2 - 30639250

AN - SCOPUS:85059700928

SN - 2405-4569

VL - 6

SP - 1195

EP - 1198

JO - European Urology Focus

JF - European Urology Focus

IS - 6

ER -

Considerations When Treating Patients with Good-risk Germ Cell Tumors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this